Market Place
Sourcing Support
Merck, Daiichi`s ADC Lung Cancer Trial Shows Promise Despite Deaths
18 Sep 2024 //
BUSINESSWIRE
ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
13 Sep 2024 //
BUSINESSWIRE
Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial
07 Sep 2024 //
BUSINESSWIRE
First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan
03 Aug 2024 //
PHARMABIZ
IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated
01 Aug 2024 //
BUSINESSWIRE
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter From FDA
26 Jun 2024 //
BUSINESSWIRE
Tropion-Lung01: Nsclc Vs Chemo Clinically Meaningful Improvement
27 May 2024 //
BUSINESSWIRE
AstraZeneca, Daiichi aim for first pan-tumor ADC approval
30 Jan 2024 //
BIOPHARMADIVE
ENHERTU granted Priority Review for patients with HER2-positive solid tumors
29 Jan 2024 //
BUSINESSWIRE
Enhertu granted Priority Review in the US for patients with solid tumours
29 Jan 2024 //
PRESS RELEASE
Seagen patent invalidated in long-running Daiichi Sankyo spat
18 Jan 2024 //
FIERCE PHARMA
After Enhertu success, Daiichi and AstraZeneca branch off
25 Oct 2023 //
FIERCE BIOTECH
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for NSCLC
23 Oct 2023 //
BUSINESSWIRE
ENHERTU Demonstrated Survival Across Multiple HER2 Expressing Solid Tumors
23 Oct 2023 //
BUSINESSWIRE
AstraZeneca-Daiichi get some clarity on Enhertu follow up med
23 Oct 2023 //
FIERCE BIOTECH
NICE poised to reject Enhertu in HER2-low breast cancer
28 Sep 2023 //
FIERCE PHARMA
CHMP recommends AstraZeneca, Daiichi`s Enhertu for HER2-mutant NSCLC
16 Sep 2023 //
PRESS RELEASE
ENHERTU Shows Strong Responses in Treated HER2-mutant Advanced Lung Cancer
11 Sep 2023 //
BUSINESSWIRE
BioNTech, DualityBio steer ADC into PhIII with Enhertu
01 Sep 2023 //
#N/A
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients
31 Aug 2023 //
BUSINESSWIRE
Enhertu wins two FDA breakthrough therapy designations
31 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan
31 Aug 2023 //
ONCLIVE
Trastuzumab Deruxtecan Approved in Japan for HER2-Mutated Metastatic NSCLC
23 Aug 2023 //
ONCLIVE
Enhertu Shows OS across multiple HER2-expressing advanced solid tumours in PII
27 Jul 2023 //
PRESS RELEASE
Expanding Definitions of HER2 Expression Mediate Role of ADCs in Breast Cancer
26 Jul 2023 //
ONCLIVE
Enhertu gains more Chinese momentum with HER2-low breast cancer approval
13 Jul 2023 //
PRESS RELEASE
Enhertu shows 37.1% response rate in HER2-expressing solid tumours
06 Jun 2023 //
BUSINESSWIRE
Daiichi Sankyo to showcase latest research towards creating new standards care
27 May 2023 //
PHARMABIZ
AstraZeneca Pharma India receives DCGI’s approval for import of cancer drug
03 May 2023 //
THEHINDUBUSINESSLINE
AZ, Daiichi`s Enhertu posts trial win in numerous cancer types
07 Mar 2023 //
FIERCE PHARMA
ENHERTU Showed Durable Responses Across Multiple HER2-expressing Tumor
06 Mar 2023 //
BUSINESSWIRE
New Ambrx CEO spies a path for ousted breast cancer med
01 Mar 2023 //
FIERCE BIOTECH
Trastuzumab Deruxtecan Garners Approval for HER2+ Metastatic Breast Cancer
25 Feb 2023 //
PRESS RELEASE
Enhertu approved in Europe for HER2-low metastatic breast cancer
27 Jan 2023 //
PRESS RELEASE
ENHERTU Type II Variation Application Validated by EMA for HER2 NSCLC
04 Jan 2023 //
BUSINESSWIRE
Enhertu recommended for approval in EU by CHMP for patients with breast cancer
19 Dec 2022 //
PRESS RELEASE
ENHERTU Approved in the EU for Patients with Previously Treated Gastric Cancer
19 Dec 2022 //
BUSINESSWIRE
Daiichi submits Enhertu sNDA to treat patients with non-small cell lung cancer
14 Dec 2022 //
PHARMABIZ
AstraZeneca exec touts Enhertu`s `game-changing` SABCS showing
09 Dec 2022 //
FIERCEPHARMA
ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%
07 Dec 2022 //
BUSINESSWIRE
Enhertu neoadjuvant trial has caveats, Daiichi exec says
07 Dec 2022 //
FIERCEPHARMA
Novartis shows PFS in breast cancer subgroups; AZ reveals Enhertu data
07 Dec 2022 //
ENDPTS
Enhertu granted full approval in Japan
25 Nov 2022 //
THEPHARMALETTER
EMA committee recommends approval of Enhertu for patients
15 Nov 2022 //
PHARMABIZ
Daiichi Sankyo dials up Enhertu projection
01 Nov 2022 //
FIERCEPHARMA
Roche nets FDA approval for HER2-low breast cancer test
06 Oct 2022 //
FIERCEBIOTECH
ENHERTU Continues to Demonstrate Clinically Meaningful Tumor Response
11 Sep 2022 //
BUSINESSWIRE
Daiichi Sankyo Make Bold Strides in Oncology Across DXd ADC Portfolio at ESMO
06 Sep 2022 //
BUSINESSWIRE
ALX & Quantum Leap Collaborative Announce the Selection of Evorpacept
15 Aug 2022 //
GLOBENEWSWIRE
FDA approves second indication for AZ & Daiichi`s Enhertu in less than a week
13 Aug 2022 //
PRESS RELEASE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2
12 Aug 2022 //
BUSINESSWIRE
Guardant Health Receives FDA Approval for Guardant360® CDx as Diagnostic
12 Aug 2022 //
BUSINESSWIRE
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy
11 Aug 2022 //
BUSINESSWIRE
ADC shrinks brain metastases in HER2+ breast cancer patients
10 Aug 2022 //
EUROPEAN PHARMACEUTICAL REVIEW
AstraZeneca and Daiichi Sankyo sprint to market after FDA clears Enhertu
08 Aug 2022 //
ENDPTS
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
05 Aug 2022 //
PRNEWSWIRE
On a roll, AstraZeneca flags looming approvals for three big drug franchises
26 Jul 2022 //
ENDPTS
